Research involving Florida Cancer Specialists & Research Institute (FCS), utilising its informatics capabilities, is featured in the latest advancements in blood cancer and related malignancy treatments at the Society for Hematologic Oncology 2024.
FCS’s Real-World Evidence team collaborates with internal and external partners to provide these insights.
This information is used to enhance treatment decisions and clinical outcomes through evidence derived from real-world data.
FCS medical oncologist and haematologist Gustavo Fonseca said: “With our robust clinical and research expertise and informatics capabilities, FCS has much to contribute to our clinical understanding and practical clinical applications across the spectrum of blood cancers and diseases.
“We look forward to joining with our colleagues to improve patient experience and outcomes.”
Earlier this year, FCS formally structured its efforts to capture real-world data from the care of over one million patients.
The data was integrated with data science to generate insights that can potentially optimise patient care and advance the discovery and development of new therapies.
The research was conducted in collaboration with Janssen Scientific Affairs.
FCS president and managing physician Lucio Gordan said: “FCS has made forward-thinking investments in the development of unique, proprietary datasets.
“These are now yielding significant insights that are directly informing clinical decisions and improving patient outcomes worldwide.”
FCS provides patients with access to clinical trials. It has helped several recently approved cancer drugs during their clinical trials.
Recently, the institute partnered with Paradigm Health to provide Florida-based patients more access to new treatment options through participation in clinical trials.
Paradigm’s advanced technology platform will enable the statewide practice to plan, recruit, and conduct trials more efficiently across its 33 early and late-phase research sites.
Furthermore, Paradigm’s platform and partnerships with global trial sponsors will enhance and expand FCS’s current clinical trial offerings.
Last month, US-based healthcare company McKesson agreed to buy a controlling stake in FCS’ Core Ventures for $2.49bn.
